Our portfolio company Loopworm, the Bengaluru based innovator tranforming silworms into protein-producing micro factrories, has raised $3.25 million in pre-Series A funding.
The round was co-led by existing investor WaterBridge Ventures and Japan’s ENRISSION INDIA CAPITAL INC.
From silkworms as living bioreactors to disrupting the economics of recombinant protein production, Loopworm is building a radically sustainable platform for biotech applications — from diagnostics to animal vaccines.
Founded in 2019 by IIT Roorkee alums Ankit Alok Bagaria and Abhi Gawri, Loopworm is commercializing a reactor-free recombinant protein platform that’s faster, cheaper, and more sustainable than traditional bioreactors. The startup already operates a 6,000‑tonne/year insect processing facility in Bengaluru and exports proteins and oils for aquaculture and pet nutrition across Europe, South America, and ASEAN.
This investment will accelerate commercialization of their platform for diagnostics, animal vaccines, and other applications with lower regulatory barriers.
At Titan Capital, we backed Loopworm early for their deep tech vision — and today, they’re exporting globally, scaling fast, and filing world-class patents.
Our portfolio company Loopworm, the Bengaluru based innovator tranforming silworms into protein-producing micro factrories, has raised $3.25 million in pre-Series A funding.
The round was co-led by existing investor WaterBridge Ventures and Japan’s ENRISSION INDIA CAPITAL INC.
From silkworms as living bioreactors to disrupting the economics of recombinant protein production, Loopworm is building a radically sustainable platform for biotech applications — from diagnostics to animal vaccines.
Founded in 2019 by IIT Roorkee alums Ankit Alok Bagaria and Abhi Gawri, Loopworm is commercializing a reactor-free recombinant protein platform that’s faster, cheaper, and more sustainable than traditional bioreactors. The startup already operates a 6,000‑tonne/year insect processing facility in Bengaluru and exports proteins and oils for aquaculture and pet nutrition across Europe, South America, and ASEAN.
This investment will accelerate commercialization of their platform for diagnostics, animal vaccines, and other applications with lower regulatory barriers.
At Titan Capital, we backed Loopworm early for their deep tech vision — and today, they’re exporting globally, scaling fast, and filing world-class patents.